| Year |
Citation |
Score |
| 2024 |
Bischoff LA, Ganly I, Fugazzola L, Buczek E, Faquin WC, Haugen BR, McIver B, McMullen CP, Newbold K, Rocke DJ, Russell MD, Ryder M, Sadow PM, Sherman E, Shindo M, et al. Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma: A Review and Multidisciplinary 2023 Update. Jama Otolaryngology-- Head & Neck Surgery. PMID 38206595 DOI: 10.1001/jamaoto.2023.4323 |
0.416 |
|
| 2023 |
Greca A, Grau L, Arbet J, Liao LM, Sosa JA, Haugen BR, Kitahara CM. Anthropometric, dietary, and lifestyle factors and risk of advanced thyroid cancer: The NIH-AARP diet and health cohort study. Clinical Endocrinology. PMID 37694684 DOI: 10.1111/cen.14970 |
0.387 |
|
| 2023 |
Pozdeyev N, Dighe M, Barrio M, Raeburn C, Smith H, Fisher M, Chavan S, Rafaels N, Shortt JA, Lin M, Leu MG, Clark T, Marshall C, Haugen BR, Subramanian D, et al. Thyroid cancer polygenic risk score improves classification of thyroid nodules as benign or malignant. The Journal of Clinical Endocrinology and Metabolism. PMID 37683082 DOI: 10.1210/clinem/dgad530 |
0.386 |
|
| 2022 |
Jeon MJ, Haugen BR. Preclinical Models of Follicular Cell-Derived Thyroid Cancer: An Overview from Cancer Cell Lines to Mouse Models. Endocrinology and Metabolism (Seoul, Korea). 37: 830-838. PMID 36604954 DOI: 10.3803/EnM.2022.1636 |
0.456 |
|
| 2021 |
Mehta V, Naraparaju A, Liao D, Davies L, Haugen B, Kopp PA, Mandel S, Nikiforov YE, Ross D, Shin JJ, Tuttle RM, Randolph GW. What's in a Name? A Cost-Effectiveness Analysis of the Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) Nomenclature Revision. Thyroid : Official Journal of the American Thyroid Association. PMID 34915744 DOI: 10.1089/thy.2021.0486 |
0.42 |
|
| 2021 |
Figge JJ, Gooding WE, Steward DL, Yip L, Sippel RS, Yang SP, Scheri RP, Sipos JA, Mandel SJ, Mayson SE, Burman KD, Folek JM, Haugen B, Sosa JA, Parameswaran R, et al. Do Ultrasound Patterns and Clinical Parameters Inform the Probability of Thyroid Cancer Predicted by Molecular Testing in Nodules with Indeterminate Cytology? Thyroid : Official Journal of the American Thyroid Association. PMID 34340592 DOI: 10.1089/thy.2021.0119 |
0.37 |
|
| 2020 |
Thor AD, Wahdan-Alaswad RS, Edgerton SM, Salem H, Kim H, Tan AC, Finlay-Schultz J, Wellberg E, Sartorius CA, Jacobsen BM, Haugen BR, Liu B. Exogenous Thyroid Hormone is Associated with Shortened Survival and Upregulation of High Risk Gene Expression Profiles in Steroid Receptor Positive Breast Cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33097494 DOI: 10.1158/1078-0432.CCR-20-2647 |
0.355 |
|
| 2020 |
Sawka AM, Alexander EK, Bianco AC, Chou R, Haugen B, Kopp PA, Pearce EN, Ross DS, Smallridge RC, Jonklaas J. Challenges in Developing Recommendations based on Low Quality Evidence in Thyroid Guidelines. Thyroid : Official Journal of the American Thyroid Association. PMID 32900277 DOI: 10.1089/Thy.2020.0448 |
0.376 |
|
| 2020 |
Pozdeyev N, Erickson T, Zhang L, Ellison K, Rivard C, Sams S, Hirsch F, Haugen BR, French J. Comprehensive Immune Profiling of Medullary Thyroid Cancer. Thyroid : Official Journal of the American Thyroid Association. PMID 32242507 DOI: 10.1089/Thy.2019.0604 |
0.415 |
|
| 2020 |
Haugen B, French J, Worden FP, Konda B, Sherman EJ, Dadu R, Gianoukakis AG, Wolfe EG, Foster NR, Bowles DW, Wirth LJ. Lenvatinib plus pembrolizumab combination therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC): Results of a multicenter phase II international thyroid oncology group trial. Journal of Clinical Oncology. 38: 6512-6512. DOI: 10.1200/Jco.2020.38.15_Suppl.6512 |
0.334 |
|
| 2019 |
Sawka AM, Gagliardi AR, Haymart MR, Sturgeon C, Bernet V, Hoff KC, Angelos P, Brito JP, Haugen BR, Kim BW, Kopp PA, Mandel SJ, Ross DS, Samuels M, Sarne DH, et al. A Survey of American Thyroid Association Members Regarding the 2015 Adult Thyroid Nodule and Differentiated Thyroid Cancer Clinical Practice Guidelines. Thyroid : Official Journal of the American Thyroid Association. PMID 31830853 DOI: 10.1089/Thy.2019.0486 |
0.504 |
|
| 2019 |
Landa I, Pozdeyev N, Knauf JA, Haugen BR, Fagin JA, Schweppe RE. Genetics of Human Thyroid Cancer Cell Lines-Response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 25: 6883-6884. PMID 31732665 DOI: 10.1158/1078-0432.Ccr-19-2531 |
0.496 |
|
| 2019 |
Landa-Lopez I, Pozdeyev N, Korch C, Marlow LA, Smallridge RC, Copland JA, Henderson YC, Lai SY, Clayman GL, Onoda N, Tan AC, Garcia-Rendueles MER, Knauf JA, Haugen BR, Fagin JA, et al. Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30737244 DOI: 10.1158/1078-0432.Ccr-18-2953 |
0.531 |
|
| 2019 |
Schweppe RE, Pozdeyev N, Pike LA, Korch C, Zhou Q, Sams SB, Sharma V, Pugazhenthi U, Raeburn C, Albuja-Cruz MB, Reigan P, LaBarbera D, Landa-Lopez I, Knauf JA, Fagin JA, ... Haugen BR, et al. Establishment and characterization of four novel thyroid cancer cell lines and PDX models expressing the RET/PTC1 rearrangement, BRAFV600E, or RASQ61R as drivers. Molecular Cancer Research : McR. PMID 30733375 DOI: 10.1158/1541-7786.Mcr-18-1026 |
0.545 |
|
| 2019 |
Mayson SE, Haugen BR. Molecular Diagnostic Evaluation of Thyroid Nodules. Endocrinology and Metabolism Clinics of North America. 48: 85-97. PMID 30717912 DOI: 10.1016/J.Ecl.2018.10.004 |
0.48 |
|
| 2018 |
Meltzer CJ, Irish J, Angelos P, Busaidy NL, Davies L, Dwojak S, Ferris RL, Haugen BR, Harrell RM, Haymart MR, McIver B, Mechanick JI, Monteiro E, Morris JC, Morris LGT, et al. American Head and Neck Society Endocrine Section clinical consensus statement: North American quality statements and evidence-based multidisciplinary workflow algorithms for the evaluation and management of thyroid nodules. Head & Neck. PMID 30561068 DOI: 10.1002/Hed.25526 |
0.355 |
|
| 2018 |
Steward DL, Carty SE, Sippel RS, Yang SP, Sosa JA, Sipos JA, Figge JJ, Mandel S, Haugen BR, Burman KD, Baloch ZW, Lloyd RV, Seethala RR, Gooding WE, Chiosea SI, et al. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study. Jama Oncology. PMID 30419129 DOI: 10.1001/Jamaoncol.2018.4616 |
0.413 |
|
| 2018 |
McIver B, Freeman JL, Shah JP, Shaha AR, Haugen BR, Cohen E, Witterick IJ, Randolph GW. Summary of the third World Congress on Thyroid Cancer. Thyroid : Official Journal of the American Thyroid Association. PMID 30303467 DOI: 10.1089/Thy.2018.0616 |
0.507 |
|
| 2018 |
Deaver KE, Haugen BR, Pozdeyev N, Marshall CB. Outcomes of Bethesda Categories III and IV Thyroid Nodules Over 5 Years and Performance of the Afirma Gene Expression Classifier: A Single-Institution Study. Clinical Endocrinology. PMID 29791966 DOI: 10.1111/Cen.13747 |
0.402 |
|
| 2018 |
Oweida AJ, Phan A, Vancourt B, Robin T, Hararah MK, Bhatia S, Milner D, Lennon S, Pike L, Raben D, Haugen BR, Pozdeyev N, Schweppe RE, Karam SD. Hypofractionated radiotherapy is superior to conventional fractionation in an orthotopic model of anaplastic thyroid cancer. Thyroid : Official Journal of the American Thyroid Association. PMID 29774792 DOI: 10.1089/Thy.2017.0706 |
0.393 |
|
| 2018 |
Sawka AM, Carty SE, Haugen BR, Hennessey JV, Kopp PA, Pearce EN, Sosa JA, Tufano RP, Jonklaas J. American Thyroid Association Guidelines and Statements: Past, Present, and Future. Thyroid : Official Journal of the American Thyroid Association. PMID 29698130 DOI: 10.1089/Thy.2018.0070 |
0.334 |
|
| 2018 |
Pozdeyev N, Gay L, Sokol ES, Hartmaier RJ, Deaver KE, Davis SN, French JD, Vanden Borre P, LaBarbera DV, Tan AC, Schweppe RE, Fishbein L, Ross JS, Haugen BR, Bowles DW. Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29615459 DOI: 10.1158/1078-0432.Ccr-18-0373 |
0.447 |
|
| 2018 |
Patel NU, Lind KE, McKinney K, Clark TJ, Pokharel SS, Meier JM, Stamm ER, Garg K, Haugen B. Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer. Ajnr. American Journal of Neuroradiology. PMID 29449283 DOI: 10.3174/Ajnr.A5554 |
0.433 |
|
| 2018 |
Giordano TJ, Haugen B, Sherman SI, Shah MH, Caoili EM, Koenig RJ. Pioglitazone Therapy of PAX8-PPARγ Fusion Protein Thyroid Carcinoma. The Journal of Clinical Endocrinology and Metabolism. PMID 29373711 DOI: 10.1210/Jc.2017-02533 |
0.484 |
|
| 2018 |
French JD, Haugen BR. Thyroid cancer: CAR T cell therapy - potential in advanced thyroid cancer? Nature Reviews. Endocrinology. 14: 10-11. PMID 29170541 DOI: 10.1038/Nrendo.2017.160 |
0.535 |
|
| 2018 |
Oweida AJ, Phan A, Vancourt B, Robin T, Raben D, Haugen B, Pozdeyev N, Schweppe R, Karam SD. Abstract 4168: Radioresistant anaplastic thyroid cancers display a unique gene signature and respond to hypofractionated radiotherapy Tumor Biology. DOI: 10.1158/1538-7445.Am2018-4168 |
0.497 |
|
| 2017 |
French JD, Haugen BR. Thyroid-Specific T Cells in Patients With Differentiated Thyroid Cancer: Implications for Immune-Based Therapies? The Journal of Clinical Endocrinology and Metabolism. 102: 2131-2132. PMID 28899074 DOI: 10.1210/Jc.2017-00058 |
0.531 |
|
| 2017 |
Tuttle RM, Haugen BR, Perrier N. The Updated AJCC/TNM Staging System for Differentiated and Anaplastic Thyroid Cancer (8th edition): What changed and why? Thyroid : Official Journal of the American Thyroid Association. PMID 28463585 DOI: 10.1089/Thy.2017.0102 |
0.445 |
|
| 2017 |
Shrestha RT, Malabanan A, Haugen BR, Levy EG, Hennessey JV. ADVERSE EVENT REPORTING IN PATIENTS TREATED WITH THYROID HORMONE EXTRACT. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. PMID 28225316 DOI: 10.4158/Ep161584.Or |
0.462 |
|
| 2017 |
Haugen BR, Sawka AM, Alexander EK, Bible KC, Caturegli P, Doherty G, Mandel SJ, Morris JC, Nassar A, Pacini F, Schlumberger M, Schuff KG, Sherman SI, Somerset H, Sosa JA, et al. The ATA Guidelines on Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of eFVPTC without Invasion to NIFTP. Thyroid : Official Journal of the American Thyroid Association. PMID 28114862 DOI: 10.1089/Thy.2016.0628 |
0.5 |
|
| 2016 |
French JD, Bible K, Spitzweg C, Haugen BR, Ryder M. Leveraging the immune system to treat advanced thyroid cancers. The Lancet. Diabetes & Endocrinology. PMID 27773653 DOI: 10.1016/S2213-8587(16)30277-7 |
0.489 |
|
| 2016 |
Haugen BR. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed? Cancer. PMID 27741354 DOI: 10.1002/Cncr.30360 |
0.539 |
|
| 2016 |
Pozdeyev N, Yoo M, Mackie R, Schweppe RE, Tan AC, Haugen BR. Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies. Oncotarget. PMID 27322211 DOI: 10.18632/Oncotarget.10010 |
0.302 |
|
| 2016 |
Bastman JJ, Serracino HS, Zhu Y, Koenig MR, Mateescu V, Sams SB, Davies KD, Raeburn CD, McIntyre RC, Haugen BR, French JD. Tumor-infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer. The Journal of Clinical Endocrinology and Metabolism. jc20154227. PMID 27045886 DOI: 10.1210/Jc.2015-4227 |
0.468 |
|
| 2016 |
Sinclair CF, Bumpous JM, Haugen BR, Chala A, Meltzer D, Miller BS, Tolley NS, Shin JJ, Woodson G, Randolph GW. Laryngeal examination in thyroid and parathyroid surgery: An American Head and Neck Society consensus statement: AHNS Consensus Statement. Head & Neck. PMID 26970554 DOI: 10.1002/Hed.24409 |
0.372 |
|
| 2016 |
Haugen B. Editorial: Centennial Celebration: An Interview with Dr Bryan Haugen on 100 Years of Thyroid Research. Molecular Endocrinology. 30: 1-2. PMID 26720254 DOI: 10.1210/Me.2015-1313 |
0.395 |
|
| 2015 |
Haugen BR, Alexander EK, Bible KC, Doherty G, Mandel SJ, Nikiforov YE, Pacini F, Randolph G, Sawka A, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward D, Tuttle RM, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid : Official Journal of the American Thyroid Association. PMID 26462967 DOI: 10.1089/Thy.2015.0020 |
0.536 |
|
| 2015 |
Patel NU, McKinney K, Kreidler SM, Bieker TM, Russ P, Roberts K, Glueck DH, Albuja-Cruz M, Klopper J, Haugen BR. Ultrasound-based clinical prediction rule model for detecting papillary thyroid cancer in cervical lymph nodes: A pilot study. Journal of Clinical Ultrasound : Jcu. PMID 26402153 DOI: 10.1002/Jcu.22309 |
0.398 |
|
| 2015 |
Pozdeyev N, Berlinberg A, Zhou Q, Wuensch K, Shibata H, Wood WM, Haugen BR. Targeting the NF-κB Pathway as a Combination Therapy for Advanced Thyroid Cancer. Plos One. 10: e0134901. PMID 26263379 DOI: 10.1371/Journal.Pone.0134901 |
0.465 |
|
| 2015 |
McLeod DS, Jonklaas J, Brierley J, Ain KB, Cooper DS, Fein HG, Haugen BR, Ladenson PW, Magner J, Ross DS, Young MS, Steward D, Xing M, Litofsky D, Maxon H, et al. Reassessing the NTCTCS staging systems for differentiated thyroid cancer, including age at diagnosis. Thyroid : Official Journal of the American Thyroid Association. PMID 26203804 DOI: 10.1089/Thy.2015.0148 |
0.418 |
|
| 2015 |
Carhill AA, Litofsky DR, Ross DS, Jonklaas J, Cooper DS, Brierley JD, Ladenson PW, Ain KB, Fein HG, Haugen BR, Magner J, Skarulis MC, Steward DL, Xing M, Maxon HR, et al. Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012. The Journal of Clinical Endocrinology and Metabolism. JC20151346. PMID 26171797 DOI: 10.1210/Jc.2015-1346 |
0.49 |
|
| 2015 |
Morrison JA, Pike LA, Lund G, Zhou Q, Kessler BE, Bauerle KT, Sams SB, Haugen BR, Schweppe RE. Characterization of thyroid cancer cell lines in murine orthotopic and intracardiac metastasis models. Hormones & Cancer. 6: 87-99. PMID 25800363 DOI: 10.1007/S12672-015-0219-0 |
0.792 |
|
| 2015 |
Klopper J, Kane M, Jimeno A, Sams S, French J, Pike L, Tompkins K, Haugen B. A Phase II Trial of Bexarotene for Advanced Differentiated Thyroid Cancer. Thyroid : Official Journal of the American Thyroid Association. 25: 563-4. PMID 25778496 DOI: 10.1089/thy.2014.0399 |
0.325 |
|
| 2015 |
Henderson YC, Ahn SH, Ryu J, Chen Y, Williams MD, El-Naggar AK, Gagea M, Schweppe RE, Haugen BR, Lai SY, Clayman GL. Development and characterization of six new human papillary thyroid carcinoma cell lines. The Journal of Clinical Endocrinology and Metabolism. 100: E243-52. PMID 25427145 DOI: 10.1210/Jc.2014-2624 |
0.5 |
|
| 2015 |
Sherman SI, Pagan M, Huang J, Lin B, Diggans J, Tom E, Haugen B, Tuttle RM, Kennedy G. Augmenting pre-operative risk of recurrence stratification in differentiated thyroid carcinoma using machine learning and high dimensional transcriptional data from thyroid FNA. Journal of Clinical Oncology. 33: 6044-6044. DOI: 10.1200/Jco.2015.33.15_Suppl.6044 |
0.384 |
|
| 2014 |
Haugen BR, Wartofsky L. In memoriam, Dr. E. Chester Ridgway, 1942-2014. The Journal of Clinical Endocrinology and Metabolism. 99: 3487-8. PMID 25279569 DOI: 10.1210/Jc.2014-3181 |
0.324 |
|
| 2014 |
Olson AC, Haugen BR, Walter J, Kwak JJ, Bagrosky BM, Koo PJ. SPECT/CT and I131 therapy of brain metastases from follicular variant papillary thyroid carcinoma (FVPTC). The Journal of Clinical Endocrinology and Metabolism. 99: 3511-2. PMID 25057877 DOI: 10.1210/Jc.2014-1875 |
0.364 |
|
| 2014 |
Bauerle KT, Schweppe RE, Lund G, Kotnis G, Deep G, Agarwal R, Pozdeyev N, Wood WM, Haugen BR. Nuclear factor κB-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8. The Journal of Clinical Endocrinology and Metabolism. 99: E1436-44. PMID 24758177 DOI: 10.1210/Jc.2013-3636 |
0.794 |
|
| 2014 |
Plantinga TS, Heinhuis B, Gerrits D, Netea MG, Joosten LA, Hermus AR, Oyen WJ, Schweppe RE, Haugen BR, Boerman OC, Smit JW, Netea-Maier RT. mTOR Inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines. The Journal of Clinical Endocrinology and Metabolism. 99: E1368-75. PMID 24712572 DOI: 10.1210/Jc.2014-1171 |
0.505 |
|
| 2014 |
Morrison JA, Pike LA, Sams SB, Sharma V, Zhou Q, Severson JJ, Tan AC, Wood WM, Haugen BR. Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer. Molecular Cancer. 13: 62. PMID 24645981 DOI: 10.1186/1476-4598-13-62 |
0.584 |
|
| 2014 |
Alexander EK, Schorr M, Klopper J, Kim C, Sipos J, Nabhan F, Parker C, Steward DL, Mandel SJ, Haugen BR. Multicenter clinical experience with the Afirma gene expression classifier. The Journal of Clinical Endocrinology and Metabolism. 99: 119-25. PMID 24152684 DOI: 10.1210/Jc.2013-2482 |
0.328 |
|
| 2014 |
Koo PJ, Klingensmith WC, Bagrosky BM, Haugen BR. SPECT/CT of metastatic struma ovarii. Clinical Nuclear Medicine. 39: 186-7. PMID 23797234 DOI: 10.1097/Rlu.0B013E3182995971 |
0.364 |
|
| 2014 |
McLeod DS, Cooper DS, Ladenson PW, Ain KB, Brierley JD, Fein HG, Haugen BR, Jonklaas J, Magner J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman For The National Thyroid Cancer Treatment Cooperative Study Group SI. Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis. Thyroid : Official Journal of the American Thyroid Association. 24: 35-42. PMID 23731273 DOI: 10.1089/Thy.2013.0062 |
0.503 |
|
| 2014 |
Sosa JA, Elisei R, Jarzab B, Balkissoon J, Lu SP, Bal C, Marur S, Gramza A, Yosef RB, Gitlitz B, Haugen BR, Ondrey F, Lu C, Karandikar SM, Khuri F, et al. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid : Official Journal of the American Thyroid Association. 24: 232-40. PMID 23721245 DOI: 10.1089/Thy.2013.0078 |
0.325 |
|
| 2013 |
Cibas ES, Baloch ZW, Fellegara G, LiVolsi VA, Raab SS, Rosai J, Diggans J, Friedman L, Kennedy GC, Kloos RT, Lanman RB, Mandel SJ, Sindy N, Steward DL, Zeiger MA, ... Haugen BR, et al. A prospective assessment defining the limitations of thyroid nodule pathologic evaluation. Annals of Internal Medicine. 159: 325-32. PMID 24026318 DOI: 10.7326/0003-4819-159-5-201309030-00006 |
0.431 |
|
| 2013 |
Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet (London, England). 381: 1058-69. PMID 23668556 DOI: 10.1016/S0140-6736(13)60109-9 |
0.55 |
|
| 2013 |
Haugen BR, Sherman SI. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocrine Reviews. 34: 439-55. PMID 23575762 DOI: 10.1210/Er.2012-1038 |
0.408 |
|
| 2013 |
Bruno TC, French JD, Jordan KR, Ramirez O, Sippel TR, Borges VF, Haugen BR, McCarter MD, Waziri A, Slansky JE. Influence of human immune cells on cancer: studies at the University of Colorado. Immunologic Research. 55: 22-33. PMID 22941561 DOI: 10.1007/S12026-012-8346-Y |
0.407 |
|
| 2012 |
Haugen BR. Radioiodine remnant ablation: current indications and dosing regimens. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 18: 604-10. PMID 22849876 DOI: 10.4158/Ep12117.Co |
0.454 |
|
| 2012 |
Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, LiVolsi VA, Mandel SJ, Raab SS, Rosai J, Steward DL, Walsh PS, Wilde JI, ... ... Haugen BR, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. The New England Journal of Medicine. 367: 705-15. PMID 22731672 DOI: 10.1056/Nejmoa1203208 |
0.432 |
|
| 2012 |
Chan CM, Jing X, Pike LA, Zhou Q, Lim DJ, Sams SB, Lund GS, Sharma V, Haugen BR, Schweppe RE. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3580-91. PMID 22586301 DOI: 10.1158/1078-0432.Ccr-11-3359 |
0.545 |
|
| 2012 |
Jonklaas J, Nogueras-Gonzalez G, Munsell M, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis MC, Steward DL, et al. The impact of age and gender on papillary thyroid cancer survival. The Journal of Clinical Endocrinology and Metabolism. 97: E878-87. PMID 22496497 DOI: 10.1210/Jc.2011-2864 |
0.396 |
|
| 2012 |
French JD, Kotnis GR, Said S, Raeburn CD, McIntyre RC, Klopper JP, Haugen BR. Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. The Journal of Clinical Endocrinology and Metabolism. 97: E934-43. PMID 22466343 DOI: 10.1210/Jc.2011-3428 |
0.453 |
|
| 2011 |
Wood WM, Sharma V, Bauerle KT, Pike LA, Zhou Q, Fretwell DL, Schweppe RE, Haugen BR. PPARγ Promotes Growth and Invasion of Thyroid Cancer Cells. Ppar Research. 2011: 171765. PMID 22194735 DOI: 10.1155/2011/171765 |
0.797 |
|
| 2011 |
Schweppe RE, Haugen BR. Thyroid targeted Kras(G12D)/Pten(-/-) mice and their cell lines: new tools to study thyroid cancer biology. Thyroid : Official Journal of the American Thyroid Association. 21: 941-4. PMID 21877921 DOI: 10.1089/Thy.2011.2109.Ed |
0.523 |
|
| 2011 |
Janssen JS, Sharma V, Pugazhenthi U, Sladek C, Wood WM, Haugen BR. A rexinoid antagonist increases the hypothalamic-pituitary-thyroid set point in mice and thyrotrope cells. Molecular and Cellular Endocrinology. 339: 1-6. PMID 21458528 DOI: 10.1016/J.Mce.2011.03.014 |
0.335 |
|
| 2010 |
Jonklaas J, Cooper DS, Ain KB, Bigos T, Brierley JD, Haugen BR, Ladenson PW, Magner J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI. Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid : Official Journal of the American Thyroid Association. 20: 1423-4. PMID 21054207 DOI: 10.1089/Thy.2010.0308 |
0.49 |
|
| 2010 |
Haugen BR, Duncan MW. Applications of proteomics to thyroid neoplasms: are we there yet? Thyroid : Official Journal of the American Thyroid Association. 20: 1051-2. PMID 20883170 DOI: 10.1089/Thy.2010.1658 |
0.465 |
|
| 2010 |
Bauerle KT, Schweppe RE, Haugen BR. Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion. Molecular Cancer. 9: 117. PMID 20492683 DOI: 10.1186/1476-4598-9-117 |
0.785 |
|
| 2010 |
Michels A, Haugen B. Malignant struma ovarii. The Journal of Clinical Endocrinology and Metabolism. 95: 1505. PMID 20375218 DOI: 10.1210/Jc.2009-2376 |
0.475 |
|
| 2010 |
French JD, Weber ZJ, Fretwell DL, Said S, Klopper JP, Haugen BR. Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. The Journal of Clinical Endocrinology and Metabolism. 95: 2325-33. PMID 20207826 DOI: 10.1210/Jc.2009-2564 |
0.511 |
|
| 2010 |
Haugen BR, Kane MA. Approach to the thyroid cancer patient with extracervical metastases. The Journal of Clinical Endocrinology and Metabolism. 95: 987-93. PMID 20203334 DOI: 10.1210/Jc.2009-2305 |
0.4 |
|
| 2010 |
De Oliveira LP, Haugen B, Kane M, Jimeno A, Klopper J. Rexinoid therapy for poorly differentiated thyroid cancer: A pilot clinical phase II trial and correlation to retinoid and peroxisome-proliferator activated receptor gamma receptors expression. Journal of Clinical Oncology. 28: TPS269-TPS269. DOI: 10.1200/Jco.2010.28.15_Suppl.Tps269 |
0.489 |
|
| 2009 |
Haugen BR. Drugs that suppress TSH or cause central hypothyroidism. Best Practice & Research. Clinical Endocrinology & Metabolism. 23: 793-800. PMID 19942154 DOI: 10.1016/J.Beem.2009.08.003 |
0.439 |
|
| 2009 |
Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid : Official Journal of the American Thyroid Association. 19: 1167-214. PMID 19860577 DOI: 10.1089/Thy.2009.0110 |
0.495 |
|
| 2009 |
Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Grasso L, Leboulleux S, Rachinsky I, Luster M, Lassmann M, Busaidy NL, et al. Follow-Up of Low-Risk Differentiated Thyroid Cancer Patients Who Underwent Radioiodine Ablation of Postsurgical Thyroid Remnants after Either Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal The Journal of Clinical Endocrinology and Metabolism. 94: 4171-4179. PMID 19850694 DOI: 10.1210/Jc.2009-0869 |
0.502 |
|
| 2009 |
Ross DS, Litofsky D, Ain KB, Bigos T, Brierley JD, Cooper DS, Haugen BR, Jonklaas J, Ladenson PW, Magner J, Robbins J, Skarulis MC, Steward DL, Maxon HR, Sherman SI. Recurrence after treatment of micropapillary thyroid cancer. Thyroid : Official Journal of the American Thyroid Association. 19: 1043-8. PMID 19772419 DOI: 10.1089/Thy.2008.0407 |
0.454 |
|
| 2009 |
Schweppe RE, Kerege AA, Sharma V, Poczobutt JM, Gutierrez-Hartmann A, Grzywa RL, Haugen BR. Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition. Thyroid : Official Journal of the American Thyroid Association. 19: 825-35. PMID 19500021 DOI: 10.1089/Thy.2008.0362 |
0.374 |
|
| 2009 |
Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K, Nikiforova MN. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. The Journal of Clinical Endocrinology and Metabolism. 94: 2092-8. PMID 19318445 DOI: 10.1210/Jc.2009-0247 |
0.478 |
|
| 2009 |
Schweppe RE, Kerege AA, French JD, Sharma V, Grzywa RL, Haugen BR. Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. The Journal of Clinical Endocrinology and Metabolism. 94: 2199-203. PMID 19293266 DOI: 10.1210/Mend.23.5.9999 |
0.466 |
|
| 2008 |
Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. The Journal of Clinical Endocrinology and Metabolism. 93: 4331-41. PMID 18713817 DOI: 10.1210/Jc.2008-1102 |
0.416 |
|
| 2008 |
Haugen BR, Cooper DS, Emerson CH, Luster M, Maciel RM, Biscolla RP, Mazzaferri EL, Medeiros-Neto G, Reiners C, Robbins RJ, Robinson BG, Schlumberger M, Yamashita S, Pacini F. Expanding indications for recombinant human TSH in thyroid cancer. Thyroid : Official Journal of the American Thyroid Association. 18: 687-94. PMID 18630995 DOI: 10.1089/Thy.2008.0162 |
0.55 |
|
| 2008 |
Klopper J, Haugen B. Can calcitonin and carcinoembryonic antigen doubling times predict progression of thyroid carcinoma Nature Clinical Practice Endocrinology & Metabolism. 4: 428-429. PMID 18542112 DOI: 10.1038/Ncpendmet0865 |
0.425 |
|
| 2008 |
Netea-Maier RT, Hunsucker SW, Hoevenaars BM, Helmke SM, Slootweg PJ, Hermus AR, Haugen BR, Duncan MW. Discovery and validation of protein abundance differences between follicular thyroid neoplasms. Cancer Research. 68: 1572-80. PMID 18316623 DOI: 10.1158/0008-5472.Can-07-5020 |
0.343 |
|
| 2008 |
Klopper JP, Berenz A, Hays WR, Sharma V, Pugazhenthi U, Janssen J, Singh M, Bissonnette RP, Haugen BR. In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 589-96. PMID 18223235 DOI: 10.1158/1078-0432.Ccr-07-0269 |
0.527 |
|
| 2007 |
Golden WM, Weber KB, Hernandez TL, Sherman SI, Woodmansee WW, Haugen BR. Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects. The Journal of Clinical Endocrinology and Metabolism. 92: 124-30. PMID 17062760 DOI: 10.1210/Jc.2006-0696 |
0.42 |
|
| 2006 |
Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid : Official Journal of the American Thyroid Association. 16: 1229-42. PMID 17199433 DOI: 10.1089/Thy.2006.16.1229 |
0.402 |
|
| 2006 |
Haugen BR. Does the metabolic activity of metastatic thyroid carcinoma correlate with prognosis? Nature Clinical Practice. Endocrinology & Metabolism. 2: 488-9. PMID 16957760 DOI: 10.1038/Ncpendmet0269 |
0.424 |
|
| 2006 |
Brown LM, Helmke SM, Hunsucker SW, Netea-Maier RT, Chiang SA, Heinz DE, Shroyer KR, Duncan MW, Haugen BR. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Molecular Carcinogenesis. 45: 613-26. PMID 16788983 DOI: 10.1002/Mc.20193 |
0.353 |
|
| 2006 |
Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 47: 648-54. PMID 16595499 |
0.429 |
|
| 2006 |
Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid : Official Journal of the American Thyroid Association. 16: 109-42. PMID 16420177 DOI: 10.1089/Thy.2006.16.109 |
0.544 |
|
| 2006 |
Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. The Journal of Clinical Endocrinology and Metabolism. 91: 878-84. PMID 16394083 DOI: 10.1210/Jc.2005-2064 |
0.435 |
|
| 2006 |
Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. The Journal of Clinical Endocrinology and Metabolism. 91: 926-32. PMID 16384850 DOI: 10.1210/Jc.2005-1651 |
0.469 |
|
| 2006 |
Copland JA, Marlow LA, Kurakata S, Fujiwara K, Wong AK, Kreinest PA, Williams SF, Haugen BR, Klopper JP, Smallridge RC. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene. 25: 2304-17. PMID 16331265 DOI: 10.1038/Sj.Onc.1209267 |
0.397 |
|
| 2006 |
Sharma V, Hays WR, Wood WM, Pugazhenthi U, St Germain DL, Bianco AC, Krezel W, Chambon P, Haugen BR. Effects of rexinoids on thyrotrope function and the hypothalamic-pituitary-thyroid axis. Endocrinology. 147: 1438-51. PMID 16306084 DOI: 10.1210/En.2005-0706 |
0.362 |
|
| 2005 |
Mambo E, Chatterjee A, Xing M, Tallini G, Haugen BR, Yeung SC, Sukumar S, Sidransky D. Tumor-specific changes in mtDNA content in human cancer. International Journal of Cancer. 116: 920-4. PMID 15856456 DOI: 10.1002/Ijc.21110 |
0.4 |
|
| 2004 |
Weber KB, Shroyer KR, Heinz DE, Nawaz S, Said MS, Haugen BR. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. American Journal of Clinical Pathology. 122: 524-31. PMID 15487449 DOI: 10.1309/Uuqte505Ptn5Qj7M |
0.472 |
|
| 2004 |
Haugen BR. Redifferentiation therapy in advanced thyroid cancer. Current Drug Targets. Immune, Endocrine and Metabolic Disorders. 4: 175-80. PMID 15379720 DOI: 10.2174/1568008043339811 |
0.516 |
|
| 2004 |
Klopper JP, Hays WR, Sharma V, Baumbusch MA, Hershman JM, Haugen BR. Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Molecular Cancer Therapeutics. 3: 1011-20. PMID 15299084 |
0.347 |
|
| 2004 |
Haugen BR. Patients with differentiated thyroid carcinoma benefit from radioiodine remnant ablation. The Journal of Clinical Endocrinology and Metabolism. 89: 3665-7. PMID 15292284 DOI: 10.1210/Jc.2004-0920 |
0.475 |
|
| 2004 |
Woodmansee WW, Haugen BR. Uses for recombinant human TSH in patients with thyroid cancer and nodular goiter. Clinical Endocrinology. 61: 163-73. PMID 15272910 DOI: 10.1111/J.1365-2265.2004.02025.X |
0.539 |
|
| 2004 |
Haugen BR, Larson LL, Pugazhenthi U, Hays WR, Klopper JP, Kramer CA, Sharma V. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. The Journal of Clinical Endocrinology and Metabolism. 89: 272-80. PMID 14715861 DOI: 10.1210/Jc.2003-030770 |
0.551 |
|
| 2003 |
McDermott MT, Woodmansee WW, Haugen BR, Smart A, Ridgway EC. The management of subclinical hyperthyroidism by thyroid specialists. Thyroid : Official Journal of the American Thyroid Association. 13: 1133-9. PMID 14751034 DOI: 10.1089/10507250360731532 |
0.433 |
|
| 2003 |
Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. The Journal of Clinical Endocrinology and Metabolism. 88: 1433-41. PMID 12679418 DOI: 10.1210/Jc.2002-021702 |
0.515 |
|
| 2003 |
Mazzaferri EL, Robbins RJ, Braverman LE, Pacini F, Haugen B, Wartofsky L, Braunstein GD, Ladenson PW, Pinchera A. Authors’ Response: A Consensus Report of the Role of Serum Thyroglobulin as a Monitoring Method for Low-Risk Patients with Papillary Thyroid Carcinoma The Journal of Clinical Endocrinology and Metabolism. 88: 4508-4509. DOI: 10.1210/Jc.2003-031041 |
0.43 |
|
| 2002 |
Sugawara M, Matsuzuka F, Fukata S, Kuma K, Moatamed F, Haugen BR. Excessive survivin expression in thyroid lymphomas. Human Pathology. 33: 524-7. PMID 12094378 DOI: 10.1053/Hupa.2002.124783 |
0.474 |
|
| 2002 |
Haugen BR, Woodmansee WW, McDermott MT. Towards improving the utility of fine-needle aspiration biopsy for the diagnosis of thyroid tumours. Clinical Endocrinology. 56: 281-90. PMID 11940037 DOI: 10.1046/J.1365-2265.2002.01500.X |
0.42 |
|
| 2002 |
Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid : Official Journal of the American Thyroid Association. 12: 37-43. PMID 11838729 DOI: 10.1089/105072502753451959 |
0.362 |
|
| 2001 |
Haugen BR. Initial treatment of differentiated thyroid carcinoma. Reviews in Endocrine & Metabolic Disorders. 1: 139-45. PMID 11704999 DOI: 10.1023/A:1010066728437 |
0.511 |
|
| 2001 |
McDermott MT, Haugen BR, Lezotte DC, Seggelke S, Ridgway EC. Management practices among primary care physicians and thyroid specialists in the care of hypothyroid patients. Thyroid : Official Journal of the American Thyroid Association. 11: 757-64. PMID 11525268 DOI: 10.1089/10507250152484592 |
0.393 |
|
| 2001 |
Haugen BR, Lin EC. Isotope imaging for metastatic thyroid cancer. Endocrinology and Metabolism Clinics of North America. 30: 469-92. PMID 11444171 DOI: 10.1016/S0889-8529(05)70195-X |
0.389 |
|
| 2001 |
Haugen BR. The risks and benefits of radioiodine therapy for thyroid carcinoma remain somewhat undifferentiated. Thyroid : Official Journal of the American Thyroid Association. 10: 971-3. PMID 11128724 DOI: 10.1089/THY.2000.10.971 |
0.319 |
|
| 2000 |
Brown NS, Smart A, Sharma V, Brinkmeier ML, Greenlee L, Camper SA, Jensen DR, Eckel RH, Krezel W, Chambon P, Haugen BR. Thyroid hormone resistance and increased metabolic rate in the RXR-γ- deficient mouse Journal of Clinical Investigation. 106: 73-79. PMID 10880050 DOI: 10.1172/Jci9422 |
0.407 |
|
| 1999 |
Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. The Journal of Clinical Endocrinology and Metabolism. 84: 3877-85. PMID 10566623 DOI: 10.1210/Jcem.84.11.6094 |
0.535 |
|
| 1999 |
Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, Duvic M. Central hypothyroidism associated with retinoid X receptor-selective ligands. The New England Journal of Medicine. 340: 1075-9. PMID 10194237 DOI: 10.1056/Nejm199904083401404 |
0.35 |
|
| 1999 |
Haugen BR. Management of the patient with progressive radioiodine non-responsive disease. Seminars in Surgical Oncology. 16: 34-41. PMID 9890738 DOI: 10.1002/(Sici)1098-2388(199901/02)16:1<34::Aid-Ssu7>3.0.Co;2-2 |
0.439 |
|
| 1998 |
Taylor T, Specker B, Robbins J, Sperling M, Ho M, Ain K, Bigos ST, Brierley J, Cooper D, Haugen B, Hay I, Hertzberg V, Klein I, Klein H, Ladenson P, et al. Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma Annals of Internal Medicine. 129: 622-627. PMID 9786809 DOI: 10.7326/0003-4819-129-8-199810150-00007 |
0.51 |
|
| 1998 |
Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, Ain KB, Bigos ST, Brierley JD, Haugen BR, Klein I, Robbins J, Sherman SI, Taylor T, Maxon HR. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid : Official Journal of the American Thyroid Association. 8: 737-44. PMID 9777742 DOI: 10.1089/Thy.1998.8.737 |
0.523 |
|
| 1998 |
Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, Haugen BR, Ho M, Klein I, Ladenson PW, Robbins J, Ross DS, Specker B, Taylor T, Maxon HR. Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer. 83: 1012-21. PMID 9731906 DOI: 10.1002/(Sici)1097-0142(19980901)83:5<1012::Aid-Cncr28>3.0.Co;2-9 |
0.475 |
|
| 1997 |
Haugen BR, Nawaz S, Markham N, Hashizumi T, Shroyer AL, Werness B, Shroyer KR. Telomerase activity in benign and malignant thyroid tumors. Thyroid : Official Journal of the American Thyroid Association. 7: 337-42. PMID 9226200 DOI: 10.1089/Thy.1997.7.337 |
0.462 |
|
| 1996 |
Wood WM, Dowding JM, Bright TM, McDermott MT, Haugen BR, Gordon DF, Ridgway EC. Thyroid hormone receptor beta2 promoter activity in pituitary cells is regulated by Pit-1. The Journal of Biological Chemistry. 271: 24213-20. PMID 8798664 DOI: 10.1074/Jbc.271.39.24213 |
0.324 |
|
| 1995 |
Haugen BR, Nawaz S, Cohn A, Shroyer K, Bunn PA, Liechty DR, Ridgway EC. Secondary malignancy of the thyroid gland: a case report and review of the literature. Thyroid : Official Journal of the American Thyroid Association. 4: 297-300. PMID 7833666 DOI: 10.1089/Thy.1994.4.297 |
0.522 |
|
| Show low-probability matches. |